Clinical Trial Update: The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study [Phase 1]

View source ↗

Summary

Phase I study evaluating the dosing regimen of Pyrotinib for HER2-positive advanced breast cancer as first-line therapy; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Breast Cancer | Phase 1 | Status: RECRUITING